May. 23 at 11:37 AM
Leerink⬆️
$FULC to OP-
$12 from MP-
$4, plus⬆️the PoS (50%) and Gross Peak Sales ests (
$600M), in SCD and said, "We see a positively skewed risk/reward heading into the data, with an up/down of +100%/-40%," ahead of
$FULC's SCD data.
$PFE $VRTX $CRSP $AGIO NVS BLUE XBI
Leerink additionally said, "Bottom Line: We are upgrading
$FULC to Outperform (from Market Perform) ahead of the 12mg SCD data, as we are intrigued by the results so far, think the HbF increase is likely to improve with longer/higher dosing, and believe the stock has more room to run, especially with growing scarcity value in the SCD space.
Herein, we revisit the results seen so far, what to expect in the next cohort, and the stock setup ahead of the next readout in early 3Q.
Leerink went on to say:
